



## **EU YAN SANG SUBSIDIARY VISTERN HEALTH SIGNS DISTRIBUTION AGREEMENT WITH MANUKA HEALTH**

**Singapore and Malaysia, 26 September 2007** – Eu Yan Sang International Ltd (Eu Yan Sang) today announced that its subsidiary, Vistern Health Sdn Bhd<sup>1</sup> (Vistern Health) has signed an agreement to distribute products manufactured by Manuka Health New Zealand Ltd (Manuka Health).

The agreement will see Manuka Health branded products distributed via Vistern Health in Malaysia and into other markets at a later stage.

Eu Yan Sang does not expect this distribution agreement to have a significant impact on the company's financial performance in the current financial year.

For additional information, please see the attached press release issued by Vistern Health.

### **Contact Information:**

#### **Eu Yan Sang International Ltd**

Ms Joanna Wong  
Vice President  
Brand Management &  
Corporate Communications  
Tel: 65-6421-3213, Fax: 65-6221 1861  
Email: [joanna.wong@euyansang.com](mailto:joanna.wong@euyansang.com)

#### **Vistern Health Sdn Bhd**

Ms Annie Ng  
Marketing Manager  
Tel: 603-9100 1509  
Email: [annieng@visternhealth.com](mailto:annieng@visternhealth.com)

---

<sup>1</sup> Vistern Health Sdn Bhd is a subsidiary of Eu Yan Sang (1959) Sdn Bhd, a wholly owned subsidiary of Eu Yan Sang International Ltd.

# NEWS RELEASE

(SEPTEMBER 2007)

---

## **Vistern Health signs agreement to distribute Manuka Health honey products**

Health products retailer Vistern Health Sdn Bhd (“VH”), a subsidiary of Eu Yan Sang (1959) Sdn Bhd (“E59”) which is wholly-owned by Eu Yan Sang International Ltd (“EYS” or the “Company”) of Singapore, has signed an agreement to distribute products manufactured by honey health science company Manuka Health New Zealand Ltd.

The deal was signed on Wednesday, 19 September 2007 by Mr Eric Chiu, General Manager and Ms Annie Ng, Marketing Manager of E59 and Dr Ray Thomson, Chairman and Mr Kerry Paul, Chief Executive Officer of Manuka Health at a ceremony in Auckland hosted by New Zealand Trade and Enterprise.

The agreement provides for distribution initially of Manuka Health branded products in Malaysia, followed by expansion into other countries.

Eu Yan Sang is a household name in traditional Chinese medicine with more than 125 retail outlets in Hong Kong, China, Macau, Malaysia and Singapore. Eu Yan Sang has been named Singapore’s “Most Valuable Brand” for the last four years.

The Company listed on the Singapore Stock Exchange has a revenue of S\$191 million in 2007. EYS also distributes products worldwide through drugstores, pharmacies, medical halls, supermarkets, convenience stores, hospitals, health clubs and spas.

EYS markets more than 280 products under its brand and more than 1,000 Chinese herbs and other medicinal products.

The group also operates a chain of 22 clinics in Singapore, Malaysia and Australia — comprising 16 TCM clinics in Singapore, three in Malaysia, and three “YourHealth” integrative medicine centres in Australia. These specialist clinics and centres combine the best practices of conventional medicine, TCM and natural therapies to provide consumers with holistic healthcare.

Manufacturing activities are carried out at two GMP (Good Manufacturing Practice) certified factories located in Hong Kong and Malaysia. The Hong Kong facility has also received certification from Australia’s Therapeutic Goods Administration.

Mr Paul said the deal added to Manuka Health’s global distribution network. The company’s Te Awamutu factory already exports more than 60 products to markets in 25 countries.

Manuka Health and EYS shared a similar business philosophy, Mr Paul said.

“We both place great importance on combining the health properties provided by nature with modern scientific evidence, to help consumers improve their health and well-being.”

Manuka Health has set up a research partnership with the Technical University of Dresden to assist in the development of the manuka honey industry in New Zealand.

Dresden researchers have identified the compound Methylglyoxal (MGO) as the active ingredient responsible for manuka honey’s anti-bacterial activity. Mr Paul said spin-off research would provide further opportunities.

A major Indian cancer research group is using MGO in trials across a wide range of different cancers with great success.

Manuka Health is also working with scientists to demonstrate the effectiveness of its Propolis products in the treatment of NF1 and NF2 neurofibromatosis, a type of tumour affecting one in 3,000 people.

“Currently there is no cure for this type of cancer, but volunteers are being treated with Manuka Health BIO 30 propolis to at least hold the onset of the cancers or best case, cure them,” Mr Paul said.

ENDS

More details on Manuka Health New Zealand Ltd and Eu Yan Sang International Ltd are available online at:

[www.manukahealth.co.nz](http://www.manukahealth.co.nz)

[www.euyansang.com](http://www.euyansang.com)